SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Shashi Gujar; John Bell; Jean Simon Diallo

doi:10.1016/j.cell.2019.01.051

SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Shashi Gujar, John Bell, Jean Simon Diallo

Medicine

Research output: Contribution to journal › Short survey › peer-review

70 Citations (Scopus)

Abstract

Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

Original language	English
Pages (from-to)	1240-1240.e1
Journal	Cell
Volume	176
Issue number	5
DOIs	https://doi.org/10.1016/j.cell.2019.01.051
Publication status	Published - Feb 21 2019

Bibliographical note

Publisher Copyright:
© 2019

ASJC Scopus Subject Areas

General Biochemistry,Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cell.2019.01.051

Cite this

@article{8bcc338fe06c44169d7de1d0b9d20b3d,

title = "SnapShot: Cancer Immunotherapy with Oncolytic Viruses",

abstract = "Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.",

author = "Shashi Gujar and John Bell and Diallo, {Jean Simon}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = feb,

day = "21",

doi = "10.1016/j.cell.2019.01.051",

language = "English",

volume = "176",

pages = "1240--1240.e1",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "5",

}

TY - JOUR

T1 - SnapShot

T2 - Cancer Immunotherapy with Oncolytic Viruses

AU - Gujar, Shashi

AU - Bell, John

AU - Diallo, Jean Simon

PY - 2019/2/21

Y1 - 2019/2/21

N2 - Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

AB - Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=85061673481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061673481&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2019.01.051

DO - 10.1016/j.cell.2019.01.051

M3 - Short survey

C2 - 30794777

AN - SCOPUS:85061673481

SN - 0092-8674

VL - 176

SP - 1240-1240.e1

JO - Cell

JF - Cell

IS - 5

ER -

SnapShot: Cancer Immunotherapy with Oncolytic Viruses

Abstract

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this